How to Get Tresiba (Insulin Degludec) in Colorado

What Is Tresiba and Why Do Colorado Patients Request It

Tresiba is a long-acting basal insulin with a duration of action exceeding 42 hours, which produces a flatter, more stable glucose-lowering profile than older basal insulins. The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, and later expanded the label to pediatric patients aged 1 year and older [1]. Novo Nordisk markets it in two concentrations: U100 (100 units/mL) and U200 (200 units/mL).

Colorado endocrinologists and primary care physicians prescribe Tresiba primarily for patients who experience nocturnal hypoglycemia on insulin glargine or insulin detemir, and for those who need dosing-time flexibility. The DEVOTE trial (N=7,637, 2-year follow-up) showed insulin degludec produced a 42% lower rate of severe hypoglycemia compared to insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001) [2]. That single finding has driven a meaningful share of Colorado prescribers to consider Tresiba as a first-line basal option for patients with hypoglycemia unawareness.

Glycemic control was non-inferior: HbA1c reduction was -1.5% with degludec vs. -1.4% with glargine across the 2-year follow-up period [2]. The FDA label confirms the pharmacodynamic half-life of approximately 25 hours and steady-state onset within 3 to 4 days of once-daily dosing [1].

Who Can Prescribe Tresiba in Colorado

Any licensed prescriber with DEA registration and Colorado state licensure may write a Tresiba prescription. Colorado grants nurse practitioners full independent prescriptive authority without a supervising physician requirement under Colorado Revised Statutes § 12-255-112 [3]. Physician assistants may prescribe under a collaborative practice agreement with a supervising physician.

That means Colorado patients can receive a valid Tresiba prescription from:

• A board-certified endocrinologist (MD or DO)
• A primary care physician or internal medicine physician
• A nurse practitioner operating an independent telehealth practice
• A physician assistant working under a documented collaborative agreement

The American Diabetes Association's 2024 Standards of Care in Diabetes state: "Basal insulin analogs (insulin glargine, insulin detemir, insulin degludec) have less nocturnal hypoglycemia than NPH insulin and are preferred in most individuals" [4]. Colorado prescribers routinely reference this guideline when writing initial basal insulin orders.

A prescriber cannot legally issue a controlled-substance prescription via audio-only telehealth, but insulin degludec is not a controlled substance. Colorado law permits synchronous audio-video telehealth encounters to establish a valid prescriber-patient relationship for non-controlled medications, which means a single video visit is sufficient to receive an insulin degludec prescription [5].

Telehealth Pathways to a Tresiba Prescription in Colorado

Telehealth is the fastest route for most Colorado residents. Under Colorado's Telehealth Act (HB 19-1098, codified at CRS § 10-16-123), insurers must reimburse telehealth encounters at parity with in-person visits for the same service [5]. This parity requirement has expanded the number of platforms offering endocrinology and diabetes telehealth in the state.

A typical telehealth workflow looks like this. The patient schedules a video visit, uploads recent labs and current medication list, and attends a 20 to 30-minute consultation. If the prescriber determines Tresiba is appropriate, an electronic prescription is sent to the patient's preferred pharmacy the same day. Most Colorado retail pharmacies stock insulin degludec U100 FlexTouch pens; U200 availability varies by location.

Platforms operating legally in Colorado must verify prescriber licensure in Colorado, conduct a synchronous (real-time) audio-video visit for the initial prescription, and maintain medical records compliant with HIPAA [6]. Patients should confirm that any telehealth service they use employs a prescriber holding an active Colorado license before the visit.

HealthRX connects Colorado patients with licensed prescribers for basal insulin evaluation. Visits typically occur within 24 to 72 hours of scheduling.

HealthRX Colorado Tresiba Access Framework:

1. Complete online intake (diabetes history, current medications, recent A1C).
2. Attend synchronous video visit with a Colorado-licensed prescriber (20 to 30 minutes).
3. Prescriber sends e-prescription to your preferred pharmacy or arranges mail-order delivery.
4. If prior authorization is needed, HealthRX clinical staff initiate the PA the same day.
5. Receive Tresiba within 3 to 10 business days depending on insurer review time.

What Labs Are Required Before Starting Tresiba in Colorado

No federal or state law mandates specific labs before insulin degludec, but every responsible prescriber will review recent metabolic data before writing the prescription. The labs requested vary by clinical context, but a standard pre-prescription workup includes:

Hemoglobin A1C. A result from within the past 3 months is preferred. The ADA defines the general HbA1c target as <7.0% for most non-pregnant adults with diabetes, with individualization based on age, hypoglycemia risk, and comorbidities [4]. Colorado telehealth prescribers routinely accept uploaded lab reports from any CLIA-certified laboratory.

Fasting plasma glucose or recent CGM data. A continuous glucose monitor (CGM) tracing from the prior 14 days gives a prescriber far more actionable data than a single fasting glucose. The 2023 ADA consensus on CGM metrics recommends a target time-in-range (70 to 180 mg/dL) of greater than 70% for most adults with type 1 diabetes [7].

Basic metabolic panel (BMP). Renal function affects insulin clearance. The FDA label for Tresiba notes that patients with renal impairment may require more frequent glucose monitoring and dose adjustments [1]. A creatinine and eGFR from within 6 months is standard.

Thyroid function (TSH). Many endocrinologists order a TSH at baseline, particularly for type 1 patients, given the high co-prevalence of autoimmune thyroid disease. A 2021 study published in Diabetes Care (N=3,042) found that 18.6% of adults with type 1 diabetes had co-existing autoimmune thyroid disease [8].

C-peptide (selective). For patients without a confirmed diabetes type, a fasting C-peptide helps distinguish type 1 from type 2 before committing to basal insulin monotherapy.

Labs can be completed at any Quest Diagnostics, LabCorp, or UCHealth lab in Colorado. Results upload directly to most telehealth platforms via HL7 integrations, or patients can photograph and upload PDF reports during the intake process.

How Prior Authorization Works in Colorado for Tresiba

Most Colorado commercial insurance plans place Tresiba on Tier 3 or Tier 4 of their formulary, which means prior authorization (PA) is almost always required before the first fill [9]. Colorado law (SB 22-132) limits insurer PA response times to 72 hours for non-urgent requests and 24 hours for urgent requests [10]. In practice, most PA decisions for Tresiba arrive within 2 to 5 business days.

A standard Tresiba prior authorization packet includes:

• Prescriber's NPI number and Colorado DEA registration (if applicable)
• Patient diagnosis codes (E10.x for type 1, E11.x for type 2)
• Documentation of trial and failure with at least one preferred basal insulin (typically insulin glargine U100 or biosimilar glargine)
• Most recent HbA1c result
• Documentation of hypoglycemia events if the clinical rationale is hypoglycemia reduction
• Letter of medical necessity if step therapy has already been met

The ADA's 2024 position statement on insulin access states: "Step therapy protocols that require patients with diabetes to fail on less expensive insulins before access to preferred agents can cause serious harm and should include clear exemption pathways" [4]. Colorado's SB 21-175 requires state-regulated health plans to apply step therapy exemptions when a patient has already tried and failed the required prior-line agent [10].

If you have already used insulin glargine or detemir and documented adverse outcomes (hypoglycemia, glucose variability, or injection-site reactions), your prescriber can use that history as the basis for a step therapy exemption request.

Colorado Medicaid and Tresiba Coverage

Colorado Medicaid (Health First Colorado) covers insulin degludec for patients with type 1 diabetes without step therapy requirements. For type 2 diabetes, coverage is conditional: the Medicaid Drug Utilization Review program requires documentation that the patient has tried at least one preferred long-acting insulin first [11].

Patients enrolled in Colorado Medicaid Managed Care Organizations (MCOs) such as Colorado Access, Rocky Mountain Health Plans, or Anthem BCBS of Colorado should verify their specific plan's formulary because MCO formularies can differ from the base Health First Colorado formulary. A pharmacist at any Colorado retail pharmacy can run a real-time eligibility check to determine your specific plan's coverage tier for NDC code 0169-3278-15 (Tresiba FlexTouch U100, 3 mL, 5-pen carton) or NDC 0169-3280-15 (U200) [1].

Paying for Tresiba in Colorado Without Insurance or With High Cost-Sharing

The cash price for one box of Tresiba FlexTouch U100 (5 pens x 3 mL = 1,500 units) ranges from approximately $315 to $420 at Colorado retail pharmacies as of mid-2025, depending on the pharmacy and any discount card applied [12].

Novo Nordisk's My$99Insulin program caps Tresiba at $99 per 30-day supply for commercially insured patients who meet income criteria [13]. GoodRx, Blink Health, and Cost Plus Drugs also list insulin degludec at negotiated rates that can reduce the out-of-pocket cost significantly below the sticker price at standard retail.

The Colorado Insulin Affordability Program (SB 21-175), active since January 2022, caps monthly cost-sharing at $100 for a 30-day insulin supply for any state-regulated health plan member [10]. This cap applies regardless of formulary tier, which means Colorado residents with commercial insurance that falls under state regulation cannot be charged more than $100 per month for Tresiba even without a prior authorization approval.

Federal employees, those on self-insured employer plans, and Medicare Part D enrollees are not covered by the state cap. Medicare Part D beneficiaries have a $35/month insulin cap under the Inflation Reduction Act, which applies to covered Part D insulins including insulin degludec where it appears on the plan's formulary [14].

Transferring a Tresiba Prescription to Colorado

If you are relocating to Colorado or spending an extended period in the state, transferring an existing Tresiba prescription is straightforward. Colorado does not require a new prescription be written by a Colorado-licensed provider if the transferring pharmacy is within the same chain (for example, Walgreens to Walgreens, or CVS to CVS). Cross-chain transfers are also permitted for non-controlled substances under Colorado pharmacy law [15].

For telehealth-issued prescriptions from an out-of-state provider, Colorado requires the prescribing provider to hold an active Colorado license or a multistate compact license recognized in Colorado. If your current out-of-state telehealth prescriber is not licensed in Colorado, you will need a new prescription from a Colorado-licensed provider before a Colorado pharmacy can dispense [5].

A transferred prescription retains the original number of authorized refills. The receiving pharmacy must verify the original prescription with the dispensing pharmacy and log the transfer in its dispensing system. Most retail chains complete this process within 24 hours.

503A Compounding Pharmacies and Insulin Degludec in Colorado

Colorado has multiple licensed 503A compounding pharmacies that may prepare customized insulin formulations. The FDA distinguishes 503A pharmacies (patient-specific, prescription-required) from 503B outsourcing facilities (bulk, hospital supply). Insulin degludec is an FDA-approved finished drug product, so a 503A pharmacy compounding it must meet specific state and federal requirements for repackaging or compounding with a valid prescription [16].

In practice, most Colorado 503A pharmacies do not compound insulin degludec from raw API because the commercial product is widely available and the regulatory risk of compounding an approved biologic is high. Patients seeking insulin degludec through a 503A pharmacy in Colorado should confirm that the pharmacy holds an active Colorado State Board of Pharmacy license and that the compounder can document the source of any API used [15].

The FDA's guidance on compounded insulin analogs notes that compounding insulin biosimilars outside of specific shortage conditions raises significant regulatory questions [16]. For almost all Colorado patients, the commercial Tresiba FlexTouch pen from a licensed retail or mail-order pharmacy is the appropriate and most legally clear pathway.

How Long Until You Receive Tresiba in Colorado

The timeline depends on whether prior authorization is needed and how you plan to fill the prescription.

Same-day or next-day. If your plan covers Tresiba without prior authorization, or if you are paying cash, a pharmacy in stock can dispense the same day the prescription is received. Most large Colorado retail chains (King Soopers Pharmacy, Walgreens, CVS, Walmart Pharmacy) carry insulin degludec or can order it for next-business-day delivery.

3 to 5 business days. If prior authorization is needed, Colorado's 72-hour commercial insurer response requirement and a 1 to 2-day pharmacy processing window typically result in a total wait of 3 to 5 business days from the date the prescriber submits the PA.

5 to 10 business days. Colorado Medicaid PA reviews can take the full statutory period, and MCO reviews may add 1 to 2 additional days. Patients on Health First Colorado should plan for up to 10 business days from the telehealth visit to the first fill.

Mail-order pharmacies such as Optum Rx, Express Scripts, and CVS Caremark ship to Colorado addresses. Standard shipping from most mail-order fulfillment centers to Colorado is 2 to 5 business days. Insulin requires cold-chain shipping (2 to 8°C), and most mail-order pharmacies use insulated packaging with gel packs that maintain temperature for 24 to 72 hours in transit [17].

Tresiba Dosing: What to Expect After Your Colorado Prescription Is Filled

Tresiba is injected subcutaneously once daily. The FDA label specifies that, unlike NPH insulin, injection timing is flexible: the dose can be given at any time of day as long as there are at least 8 hours between consecutive injections [1]. This makes it particularly practical for patients with variable schedules, a population common among Colorado's large outdoor recreation and shift-work communities.

Starting doses for type 2 diabetes naive to basal insulin are typically 10 units once daily or 0.1 to 0.2 units/kg/day, titrated every 3 to 4 days based on fasting glucose [4]. For patients converting from another basal insulin on a unit-for-unit basis, the DEVOTE trial used a pre-specified fasting glucose titration target of 71 to 90 mg/dL [2].

Injection sites in Colorado's high-altitude, low-humidity environment should be rotated systematically. The FDA label recommends rotating within the same anatomic region (abdomen, thigh, or upper arm) rather than switching regions randomly to minimize absorption variability [1]. Absorption from the abdomen is slightly faster than from the thigh; the difference is clinically relevant in type 1 patients on intensive regimens [18].

Storage before opening: refrigerate at 36 to 46°F (2 to 8°C). After first use, the pen may be stored at room temperature (<86°F / 30°C) for up to 56 days, longer than any other currently available basal insulin [1]. At Colorado's high-altitude summer temperatures, this room-temperature window may shorten; patients hiking or camping should use an insulated case and avoid direct sunlight.